News

EO-3021 is designed for GC/GEJ patients whose tumours express Claudin 18.2 and have progressed following prior therapy. The FTD status aims to accelerate the development and review of

The treatment targets those with folate receptor alpha (FRα)-positive, platinum-resistant, and high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three treatment

The product is the result of a collaboration with the Agency for Science, Technology, and Research (A*STAR), featuring patented active pH control technology to address the skin condition.

This topical therapy is aimed at treating moderate to severe skin rash. Azitra CEO Francisco Salva said: “Many cancer patients receive EGFR inhibitors, which often have significant side

This designation will offer potential benefits such as tax credits and fee waivers to facilitate the drug’s development. The ODD status is intended for potential treatments for diseases

This collaboration is pivotal as GBS remains a significant cause of severe infections in newborns, accounting for nearly half of all life-threatening cases. With 15-25% of the population,

This vaccine is intended for individuals aged 12 and above and is now stocked at pharmacies including CVS Pharmacy, Walgreens, Rite Aid among others. The vaccine has been

This approval is based on results from a multicentre, randomised, double-blind, placebo-controlled Phase III trial. The study’s co-primary endpoints were achieving a minimum of a 75% improvement in

EN001, a clinical-stage mesenchymal stem cell therapy in ENCell’s pipeline, is developed using mesenchymal stem cells sourced from the early culture stage. Preclinical studies are said to have